I'm a cardiologist. The companies that win the next era of medicine won't be the ones with the best chatbots. They'll be the ones with intelligence embedded in the actual work of understanding life — and fixing what breaks inside us. Anthropic just made a loud, calculated move onto that board. And the rest of the industry is already paying for the privilege. Last week they launched Claude Science — an AI research workbench built not as a chatbot, but as an operating environment for drug discovery. 60+ built-in scientific functions spanning genomics, proteomics, structural biology, and cheminformatics. It designs CRISPR screens. Analyzes single-cell RNA sequencing. Renders 3D protein structures. Reads genome maps. It plugs into the world's largest biological dataset — millions of microbial species — and compresses weeks of research per pathogen into a single conversation. The CEO, Dario Amodei, said something that stopped me: until now, humans have wrestled with the full complexity of biology using only our minds. He believes AI will do for life sciences what it already did for software engineering — and he's put real weight behind it. He's argued that powerful AI could compress 50 to 100 years of biological progress into 5 to 10. Here's why this matters to a practicing physician. Every breakthrough I've written about on this platform — the gene editing that permanently lowers cholesterol, the personalized mRNA cancer vaccines, the AI that diagnosed 18 children specialists couldn't, the cell therapies making diabetics insulin-free, the CAR-Tregs engineered to calm inflamed arteries — every one of them required a research process that took years and cost fortunes. The bottleneck was never human brilliance. It was the sheer, crushing complexity of biology outpacing the speed at which any human team could analyze it. That bottleneck is what's being dismantled. And the industry is voting with its money. Bristol Myers Squibb rolled Claude out to 30,000 employees across research, clinical development, and manufacturing. Sanofi says most of its scientists use it daily. OpenAI signed Novo Nordisk, Eli Lilly, Moderna. The AI arms race that reshaped software is now reshaping the discovery of medicine itself. The part I find most striking: Anthropic isn't just selling the tool. It's using Claude Science to run its own drug discovery program — deliberately targeting neglected diseases that traditional pharma finds unprofitable. The rare conditions. The forgotten patients. The diseases that were never worth a billion-dollar development budget under the old economics. If AI collapses the cost and time of discovery, the math that left millions of rare-disease patients with no treatment gets rewritten. I've said for months that we're living through the most extraordinary period in medical history — gene editing, cell therapy, personalized vaccines, cellular reprogramming, all arriving at once. What I didn't fully appreciate until now is the engine underneath the acceleration. It's this. Intelligence pointed directly at the complexity of life. The doctors of the next generation won't just prescribe the breakthroughs. They'll practice in a world where the breakthroughs arrive at a pace we can barely imagine — because the thing that always limited us, the complexity of biology itself, finally met something built to understand it. The board is being set. The serious players are already seated. And the winners won't be measured in better conversations. They'll be measured in cures.